

ONCODAILY MEDICAL JOURNAL

abstract

Treatment of transplant-associated thrombotic microangiopathy with Ravulizumab: Experience of N.N. Blokhin center for 2 patients


Natalia Burlaka et al

DOI: 10.69690/ODMJ-018-0425-1833



SIOP Asia, 2025, Saudi Arabia

abstract



Treatment of transplant-associated thrombotic microangiopathy with Ravulizumab: Experience of N.N. Blokhin center for 2 patients

Authors: Natalia Burlaka, Kirill Kirgizov, Irina Costareva, Karina Sergeenko, Timur Z. Aliev, Elena B. Machneva, Tatyana Potemkina, Konstantin Mitrakov, Mariya Malova, Daria Smirnova, Nara Stepanyan, Natalia Batmanova, Meri Shervashidze, Timur Valiev, Svetlana Varfolomeeva

Affiliation: Lev Durnov Research Institute of Pediatric Oncology and Hematology of Nikolay Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation

DOI: [10.69690/ODMJ-018-0425-1833](https://doi.org/10.69690/ODMJ-018-0425-1833)

Introduction: Treatments of transplant-associated thrombotic microangiopathy (TA-TMA) in children after the allogeneic hematopoietic stem cell transplantation (aHSCT) still a challenging problem. New approaches required.

Methodology: This is a retrospective study analyzing the experience of ravulizumab treatment of refractory TA-TMA in children after aHSCT. We aimed to present the single center experience of safety, tolerability and efficacy of ravulizumab therapy for children with TA-TMA.

Results: We present 2 cases of patients with high-risk TA-TMA diagnosed with both laboratory test and clinical assessment. Patient 1: 17 y.o. girl with secondary AML (after Osteosarcoma). Patient 1 received 2 courses of chemotherapy with AML BFM-oriented protocol and aHSCT from matched unrelated donor (MUD), conditioning regimen

includes treosulfan, melphalan and fludarabine. IST included ruxolitinib, ATG and abatacept. TA-TMA started at day 60 after aHSCT with elevated LDH levels, thrombocytopenia, proteinuria, high blood pressure and schistocytosis. Ravulizumab infused 3 times in standard ("adult") dose with the effect. No signs of TA-TMA found in patients at day +200. Patient 1 is alive. Patient 2: 17 y.o. girl with Ph-pos. ALL received aHSCT from MUD, conditioning regimen: TBI, fludarabine and etoposide. IST included tacrolimus, ATG and abatacept. At day +250 chronic graft-versus-host disease (cGvHD) diagnosed. GvHD were treated with multiple therapies including sirolimus, etanercept and belumosudil – cGvHD is under control now. TA-TMA was diagnosed at day +370 with elevated LDH levels, thrombocytopenia, proteinuria, high blood pressure and schistocytosis. Ravulizumab infused 2 times in standard ("adult") dose with the effect.

Conclusion: Ravulizumab is a safe, well-tolerated and effective method of TA-TMA treatment in children after aHSCT. Future multicenter studies required.